Please contact us for more information or to learn if you are eligible to participate.
To evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo
Principal Investigator | Fernando Membreno, MD |
Co-PI | John Rodriguez |
Sponsor | Madrigal Pharmaceuticals, Inc |
Type of Trial | Interventional |